The FDA said today it is planning to rescind its approval of Genentech’s bevacizumab (Avastin) as a treatment for breast cancer. The drug, a targeted antibody drug that chokes off blood flow to tumors, is also approved for colon and lung cancer, and will remain so. The benefits of using the treatment for breast cancer has been more controversial, particularly since July, when an FDA advisory panel voted 12-1 in favor of withdrawing the breast cancer approval, as noted today by Andrew Pollack of the New York Times. Genentech, a unit of Switzerland-based Roche, plans to request a hearing to appeal the decision, the company said in a statement.
By posting a comment, you agree to our terms and conditions.